Amy Wehn
Executive Director & Head, Companion Diagnostics and Clinical Biomarkers Tango Therapeutics
Seminars
Tuesday 6th October 2026
Panel Discussion: Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization
12:30 pm
- At what point in therapeutic development should a sponsor begin thinking seriously about a CDx strategy and what are signs that teams may already be late?
- How are technologies such as digital pathology, NGS, liquid biopsy, multiplex testing, AI-enabled analysis, or bioinformatics changing the traditional CDx development model?
- What needs to change in how pharma and diagnostic companies collaborate to make CDx development more efficient, globally scalable, commercially successful, and ultimately better for patients?
